Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Fig. 3

Serum cytokines modulation after NEO-201 infusion. Serum cytokines were evaluated using the V-PLEX Proinflammatory Panel 1 Human Kit. The figure depicts modulation of serum levels of cytokines statistically significant after NEO-201 treatments at different time points compared to baseline levels before treatment (C1PRE). A. Comparison of IL-10 median serum levels prior and post treatment. B. Comparison of TNF-α median serum levels prior and post treatment. C. comparison of IL-8 median serum levels prior and post treatment. D. comparison of IL-6 median serum levels prior and post treatment. * statistically significant (p < 0.05) by 2way ANOVA; ** statistically significant (p < 0.01) by 2way ANOVA; *** statistically significant (p < 0.001) by 2way ANOVA

Back to article page